Amsterdam-based VectorY Therapeutics has announced €74.5m ($83.5m) in new financing, with Invest-NL contributing €7m alongside fellow first-time backers Angelini Ventures and the European Investment Bank.
VectorY Therapeutics, a clinical-stage biotech developing vectorised antibody therapies for neurodegenerative diseases, announced the new financing on 11 November in a press release from Amsterdam and Boston. The money is earmarked for its clinical and preclinical pipeline, led by an ALS programme now in a phase 1/2 study.
Invest-NL confirmed the size of its own ticket the same day. In its announcement, the investor said it is putting €7m into VectorY and that the investment is part of the €74.5m round.
The new investors named in the release are Angelini Ventures, Invest-NL and the European Investment Bank (EIB). The returning investors it names are Forbion (through its Growth and Ventures strategies), EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures (BGV), Eli Lilly and Company and the ALS Investment Fund.
The raise follows the €129m ($138m) Series A that VectorY announced in November 2023. That round was co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund, with participation from MRL Ventures Fund (a corporate venture arm of Merck & Co.), Insight Partners, the ALS Investment Fund, Forbion Ventures and BGV, among others.
The lead asset is VTx-002, a vectorised antibody designed to target pathological TDP-43, a protein that the company says aggregates abnormally in up to 97% of ALS patients. The therapy is designed to drive sustained antibody production inside the central nervous system. It is investigational and has not been approved by any regulator.
Proceeds will carry VTx-002 through key clinical milestones, including the final readout of PIONEER-ALS. The global, open-label, dose-escalation study is testing two dose levels in adults with ALS at sites in the US, Europe and the UK. In September 2026, VectorY announced the expansion of the study from 12 to 36 participants.
Chief executive Jim Scibetta said the financing reflects "strong confidence in our team, our platform and the potential of our pipeline".
Invest-NL described VectorY as being at the stage where clinical research focuses on the safety of the treatment and on first indications of efficacy. The investor added that many Dutch biotech companies struggle to raise enough money to develop and test new treatments, and that its role is to help close that funding gap.
Beyond ALS, the round will support VTx-003 for Huntington's disease and further programmes. VectorY's pipeline also lists VTx-004, which targets TDP-43 in frontotemporal dementia, and VTx-005, which targets phosphorylated tau in Alzheimer's disease.
Original source: VectorY Therapeutics (press release), "VectorY Therapeutics Raises €74.5 Million ($83.5 Million) to Advance Clinical and Preclinical Neurodegenerative Disease Pipeline"; Invest-NL (press release), "Invest-NL invests €7 million in developing new technology to combat ALS"; VectorY Therapeutics (press release, November 2023), "VectorY Raises €129 Million ($138 Million) Series A Financing"





